7.61

0.26% +0.02

Tango Therapeutics Inc (TNGX)

Overview News Price History Option Chain Financials Why TNGX Down? Discussions Forecast

Tango Therapeutics Inc stock is currently priced at $7.61, with a 24-hour trading volume of 343.07K. It has seen a +0.26% increased in the last 24 hours and a -0.91% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $7.53 pivot point. If it approaches the $7.73 resistance level, significant changes may occur.

Previous Close:

$7.59

Open:

$7.76

24h Volume:

343.07K

Market Cap:

$812.26M

Revenue:

$36.53M

Net Income/Loss:

$-101.74M

P/E Ratio:

-6.2893

EPS:

-1.21

Net Cash Flow:

$-119.51M

1W Performance:

+2.28%

1M Performance:

-0.91%

6M Performance:

-9.40%

1Y Performance:

+134.88%

1D Range:

$7.49

$7.93

52W Range:

$2.47

$13.03

Tango Therapeutics Inc Stock (TNGX) Company Profile

Name

Tango Therapeutics Inc

Sector

Healthcare (1213)

Industry

Biotechnology (699)

Phone

857 320 4900

Address

100 Binney Street, Suite 700, Cambridge

Employee

Twitter

Next Earnings Date

2024-06-05

Latest SEC Filings

TNGX's Discussions on Twitter

Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-08-23	Initiated	B. Riley Securities	Buy
Oct-20-22	Upgrade	H.C. Wainwright	Neutral → Buy
Sep-20-21	Initiated	SVB Leerink	Outperform

Tango Therapeutics Inc Stock (TNGX) Latest News

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates

Zacks Investment Research

Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024

GlobeNewswire Inc.

Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference

GlobeNewswire Inc.

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

Zacks Investment Research

Tango Therapeutics Inc Stock (TNGX) Financials Data

Tango Therapeutics Inc (TNGX) Revenue 2024

TNGX reported a revenue (TTM) of $36.53 million for the quarter ending December 31, 2023, a +46.93% rise year-over-year.

Tango Therapeutics Inc (TNGX) Net Income 2024

TNGX net income (TTM) was -$101.74 million for the quarter ending December 31, 2023, a +5.95% increase year-over-year.

Tango Therapeutics Inc (TNGX) Cash Flow 2024

TNGX recorded a free cash flow (TTM) of -$119.51 million for the quarter ending December 31, 2023, a -2.34% decrease year-over-year.

Tango Therapeutics Inc (TNGX) Earnings per Share 2024

TNGX earnings per share (TTM) was -$1.08 for the quarter ending December 31, 2023, a +12.20% growth year-over-year.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.